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English speaker; 4) comparison of original and back translation;
and 5) review by a clinician. RESULTS: Cultural and linguistic
challenges emerged during the process. On the cultural level, the
differences in the approach to suicide and its methods based on
differences in tradition and availability of means required ﬁnding
suitable alternatives in the target languages.On the linguistic level,
it was important to differentiate between medical and psychiatric
hospitalisation after a suicide attempt and appropriate solutions
across languages had to be found. The process revealed an area of
ambiguity in the original rating instructions which had to be
clariﬁed in the translations. Examples of these and other chal-
lenges and their solutions will be discussed in the presentation.
CONCLUSIONS: The 45 language versions, of the C-SSRS (a
total of over 90 translations now exist), were established accord-
ing to a rigorous methodology to ensure conceptual equivalence
and cultural relevance across languages. The translations may
now be used in international studies to assess suicidal ideation and
behaviour and facilitate the comparison and pooling of data. The
analysis of the psychometric results will be necessary to see if and
how suicidal ideation and behaviour compare across countries
and cultures.
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INTRODUCTION: The EMEA reﬂection paper on HRQL
speciﬁes that the claim in the Summary of Product Characteris-
tics (SmPC) with respect to HRQL will always be considered
depending on the strength of the evidence, which should be
based on 6 criteria, amongst these are the justiﬁcation of the
choice of the HRQL instrument(s), and the evidence of valida-
tion (including for translation). To meet these requirements,
users should have access to reliable and updated information. To
determine if these can be met, it is necessary to review how users
access information about HRQL instruments. OBJECTIVES: 1)
To investigate how developers organize the release of informa-
tion about their instrument; 2) to comment on the pros and cons
for each identiﬁed dissemination strategy; 3) To make recom-
mendations for instrument developers to facilitate users’ access
to information. METHODS: we conducted a review of the
2,850 information requests addressed to our Information
Resources Centre in 2007. The requests were categorized
according to the type of information needed: 1) information
about the original instrument; 2) conditions of access/use of
instruments/translations; 3) validity of instruments/translations;
4) translation certiﬁcation; 5) intellectual property. To address
these, we made 900 contacts with developers, translators, pub-
lishers and other licensing authorities. RESULTS: Out of the
dissemination strategies identiﬁed and reviewed, ﬁve trends
emerged between two extremes: 1) uncontrolled, de-centralized,
free access to non-updated information without developer’s
input; 2) controlled, copyright-protected, centralized, fee-paying
access to reliable and updated information with developer’s
input. Advantages and disadvantages of strategies will be dis-
cussed. Examples demonstrate that the controlled strategy is
more compliant with the EMEA evidence requirements. CON-
CLUSION: Findings indicate that how a user can comply or not
with the EMEA requirements is directly related to how develop-
ers organize the release of information about their questionnaire
and translations. Promoting a controlled, centralized system
with developers’ input may facilitate access to reliable and
updated information.
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OBJECTIVES: To determine if the European Organization for
Research and Treatment of Cancer Quality of Life Question-
naire (EORTC QLQ-C30) can satisfactorily predict EQ-5D,
SF-6D and 15D utilities. The QLQ-C30 measures health-related
quality of life (HRQOL) using a global scale, ﬁve functional
scales and eight symptom scales/items and like most HRQOL
instruments provides a proﬁle of scores instead of an overall
preference-based index, precluding its use in cost-utility studies.
METHODS: A stratiﬁed sample (N = 48) of gastrointestinal
cancer patients on chemotherapy was interviewed. The survey
contained the QLQ-C30, the SF-36, two multi-attribute utility
instruments (EQ-5D and 15D) and socio-demographic and
disease-related questions. Validity of QLQ-C30 scales was
assessed by testing a priori hypotheses that they would be mod-
erately or strongly correlated with SF-36 scales measuring
similar HRQOL dimensions and that younger subjects and those
not reporting comorbid conditions would have better scores.
Linear regression analyses identiﬁed the extent to which QLQ-
C30 scales could predict EQ-5D, SF-6D and 15D utilities.
RESULTS: Pearson’s correlations between similar QLQ-C30
and SF-36 scales ranged from 0.69 to 0.89 (P < 0.001). Subjects
with coronary heart disease had worse scores on all QLQ-C30
functional scales (T-test, P < 0.05 for four scales), as did older
subjects as well (ANOVA, P < 0.05 for ﬁve scales). QLQ-C30
global, functional and symptom scales were signiﬁcant predic-
tors of utility scores elicited from standard instruments. Speciﬁ-
cally, three scales were signiﬁcant (P < 0.05) predictors of
EQ-5D utilities, six scales (P < 0.05) of SF-6D utilities and four
scales (P < 0.001) of 15D utilities and explained large portions
of variance (adjusted R2 was 0.610, 0.833 and 0.912 respec-
tively). Robustness of results was tested and conﬁrmed in patient
subgroups with differing HRQOL. CONCLUSIONS: Prelimi-
nary evidence has been provided supporting the appropriateness
mainly of the 15D and SF-6D instruments in cancer-speciﬁc
cost-utility studies, although further studies involving larger and
more diverse patient samples are encouraged.
PODIUM SESSION II: CARDIOVASCULAR
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OBJECTIVES: Therapies may reduce short-term rates of non-
fatal myocardial infarction (MI) while having no detectable effect
on in-trial mortality. We sought to estimate the clinical beneﬁt of
preventing a non-fatal MI in terms of its effects upon long-term
rates of death and MI. METHODS: We analyzed 14,890 patients
with signiﬁcant coronary artery disease (CAD) undergoing diag-
nostic catheterization (cath) at Duke Medical Center between
1999 and 2006, with follow-up through June 2007. Patients
were classiﬁed as having a non-fatal MI within three months of
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